Condition: Colon Carcinoma · Sponsor: The Netherlands Cancer Institute
In this exploratory study, patients with stage 1-3 adenocarcinoma of the colon with no signs of distant metastases will be treated with short-term immunotherapy + novel IO combinations (i.e. anti-IL 8, COX2-inhibitors, anti-LAG3). This treatment will be given during the window period until surgical resection of the tumor. The duration of treatment will be in between approximately 6 and 12 weeks.
This description comes directly from the study's public registry record.
Marieke van de Belt · +3120512 · m.vd.belt@nki.nl
Always discuss trial participation with your own doctor first.
| Marieke van de Belt | Amsterdam, Netherlands | Recruiting |
| OLVG | Amsterdam, Netherlands | Recruiting |
| Catharina Ziekenhuis | Eindhoven, Netherlands | Recruiting |
| Spaarne Ziekenhuis | Haarlem, Netherlands | Recruiting |
| Tergooi | Hilversum, Netherlands | Not Yet Recruiting |
| Haga ziekenhuis | The Hague, Netherlands | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03026140